You can buy or sell KNSA and other stocks, options, ETFs, and crypto commission-free!
Kiniksa Pharmaceuticals, Ltd. Class A Common Stock, also called Kiniksa Pharmaceuticals, is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Read More Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.
52 Week High
52 Week Low
North America (Non-US/Canada)
Seeking AlphaMar 18
Kiniksa Pharmaceuticals (KNSA) Presents At American College of Cardiology's 68thAnnual Scientific Session - Slideshow
The following slide deck was published by Kiniksa Pharmaceuticals, Ltd. in conjunction with this event. 1 37 Click to enlarge Notes:...
PR NewswireFeb 27
Global Recurrent Pericarditis Maket Epidemiology and Market Forecasts 2017-2028: Rilonacept (Kiniksa Pharmaceuticals, Ltd.) is the First Immunosuppressant to be Launched in All of the 7 Major Markets
DUBLIN, Feb. 27, 2019 /PRNewswire/ -- The "Recurrent Pericarditis - Market Insights, Epidemiology and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering. Recurrent Pericarditis - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Recurrent Pericarditis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan....
Expected May 9, Pre-Market